Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1991 2
1992 2
1993 1
2007 1
2009 1
2010 2
2012 3
2013 1
2014 1
2015 1
2016 1
2017 1
2018 2
2019 3
2020 3
2021 6
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents.
Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P, Sirivichayakul C, Watanaveeradej V, Rivera L, Espinoza F, Fernando L, Dietze R, Luz K, Venâncio da Cunha R, Jimeno J, López-Medina E, Borkowski A, Brose M, Rauscher M, LeFevre I, Bizjajeva S, Bravo L, Wallace D; TIDES Study Group. Biswal S, et al. N Engl J Med. 2019 Nov 21;381(21):2009-2019. doi: 10.1056/NEJMoa1903869. Epub 2019 Nov 6. N Engl J Med. 2019. PMID: 31693803 Clinical Trial.
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2023 May;13(2_suppl):568S-591S. doi: 10.1177/21925682231173597. Global Spine J. 2023. PMID: 37222100 Free PMC article. No abstract available.
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators. Tempero MA, et al. J Clin Oncol. 2023 Apr 10;41(11):2007-2019. doi: 10.1200/JCO.22.01134. Epub 2022 Dec 15. J Clin Oncol. 2023. PMID: 36521097 Free PMC article. Clinical Trial.
At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently assessed DFS was 19.4 (nab-paclitaxel + gemcitabine) versus 18.8 months (gemcitabine; hazard ratio [HR], 0.88; 95% CI, 0.729 to 1.063; P …
At primary data cutoff (December 31, 2018; median follow-up, 38.5 [interquartile range [IQR], 33.8-43 months), the median independently asse …
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.
Yoshino T, Andre T, Kim TW, Yong WP, Shiu KK, Jensen BV, Jensen LH, Punt CJA, Smith D, Garcia-Carbonero R, Alcaide-Garcia J, Gibbs P, de la Fouchardiere C, Rivera F, Elez E, Le DT, Adachi N, Fogelman D, Marinello P, Diaz LA Jr. Yoshino T, et al. Cancer Sci. 2023 Mar;114(3):1026-1036. doi: 10.1111/cas.15650. Epub 2022 Dec 12. Cancer Sci. 2023. PMID: 36369901 Free PMC article. Clinical Trial.
Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
COVIDSurg Collaborative. COVIDSurg Collaborative. Lancet Oncol. 2021 Nov;22(11):1507-1517. doi: 10.1016/S1470-2045(21)00493-9. Epub 2021 Oct 5. Lancet Oncol. 2021. PMID: 34624250 Free PMC article. Clinical Trial.
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted hazard ratio [HR] 0.81, 95% CI 0.77-0.84; p<0.0001), and full lockdowns with a 15.0% rate (1775 of 11 827; HR 0.51, 0.50-0.53; p …
Light restrictions were associated with a 0.6% non-operation rate (26 of 4521), moderate lockdowns with a 5.5% rate (201 of 3646; adjusted h …
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study.
COVIDSurg Collaborative; GlobalSurg Collaborative. COVIDSurg Collaborative, et al. Anaesthesia. 2021 Nov;76(11):1454-1464. doi: 10.1111/anae.15560. Epub 2021 Aug 9. Anaesthesia. 2021. PMID: 34371522 Free article. Clinical Trial.
Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0%, respectively), isolation was associated with higher rates of postoperative pulmonary complications after adjustment (adjusted OR 1.20, 95% …
Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0% …
Prognostic factors in cancer patients infected with SARS-CoV-2: a Latin American country results.
Ruiz-Garcia E, Peña-Nieves A, Alegria-Baños J, Cornejo-Juarez P, Meneses-García A, Rivera SR, Sánchez JJ, Gerson-Cwilich R, Gerson DS, Franco HM, Buerba GA, Espinoza AA, Mijares NV, Fernández-Figueroa EA, Vázquez RA, Vilar-Compte D. Ruiz-Garcia E, et al. Ther Adv Chronic Dis. 2021 Sep 26;12:20406223211047755. doi: 10.1177/20406223211047755. eCollection 2021. Ther Adv Chronic Dis. 2021. PMID: 34729153 Free PMC article.
This study found that the prognostic factors that reduced the odds of death were gender (OR = 0.42, p = 0.031) and oxygen saturation (OR = 0.90, p = 0.0001); meanwhile, poor ECOG (OR = 5.4, p = 0.0001), active disease (OR = 3.9, p = 0.041), dyspnea (OR …
This study found that the prognostic factors that reduced the odds of death were gender (OR = 0.42, p = 0.031) and oxygen saturation …
Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study.
De la Rosa Carrillo D, Martínez-García MÁ, Barreiro E, Tabernero Huguet E, Costa Sola R, García-Clemente MM, Celorrio Jiménez N, Rodríguez Pons L, Calero Acuña C, Rodríguez Hermosa JL, Golpe R, Dacal Quintas R, Sánchez-Cuéllar S, Torres Arroyo I, Blanco Aparicio M, Almadana Pacheco V, Miravitlles M; Study group on the effectiveness of inhaled antibiotic treatment in COPD; Study group on the effectiveness of inhaled antibiotic treatment in COPD. De la Rosa Carrillo D, et al. Arch Bronconeumol. 2022 Jan;58(1):11-21. doi: 10.1016/j.arbres.2021.03.009. Epub 2021 Mar 19. Arch Bronconeumol. 2022. PMID: 33849721 Free article. English, Spanish.
After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (-33.3%; P<.001), hospital admissions (-33.3%; P<.001) and hospitalization days (-26.2%; P=.003). ...We found a significant reduction in …
After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (-33.3%; P<.00 …
Conflict of Interest Disclosures.
[No authors listed] [No authors listed] Global Spine J. 2024 May;14(4_suppl):690S-714S. doi: 10.1177/21925682241245615. Global Spine J. 2024. PMID: 38726630 Free PMC article. No abstract available.
39 results